Evidence map›Paper›PMID 33250274›Full record

ReviewTrends in pharmacological sciences2021

Developing Insulin Delivery Devices with Glucose Responsiveness.

Zejun Wang, Jinqiang Wang, Anna R Kahkoska, John B Buse, Zhen Gu

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in pharmacological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Emergence of microneedles as a potential therapeutics in diabetes mellitus.Environmental science and pollution research international · 2022
    Review
  12. Review
  13. Stimuli-responsive transdermal microneedle patches.Materials today (Kidlington, England)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Zejun WangDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095, USA.
Jinqiang WangDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095, USA; College of Pharmaceutical Sciences, Zhejiang University, 310058 Hangzhou, China.
Anna R KahkoskaDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
John B BuseDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA. Electronic address: john_buse@med.unc.edu.
Zhen GuDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095, USA; College of Pharmaceutical Sciences, Zhejiang University, 310058 Hangzhou, China; California NanoSystems Institute, University of California, Los Angeles, CA 90095, USA. Electronic address: guzhen@zju.edu.cn.
University of North Carolina at Chapel Hill · USZhejiang University · CNUniversity of California, Los Angeles · US

Funding

Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
Final clinical studies for submission of a pre-market approval application to the FDA for a Bionic Pancreas that automates type 1 diabetes managementUC4DK108612 · NIDDK · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI BECK, ROY W., DAMIANO, EDWARD · 2015 to 2016
$13.5M
Pilot & Feasibility ProgramP30DK124723 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI P Darrell Neufer · 2020 to 2026
$11.0M
Towards Glucose Transporter-Mediated Glucose-Responsive Insulin Delivery with Fast ResponseR01DK112939 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LI, SONG · 2018 to 2022
$2.2M
Characterizing Impulsivity as a Determinant of Weight and Glycemic Control in Youth with Type 1 DiabetesF30DK113728 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAHKOSKA, ANNA RACHEL · 2017 to 2020
$171k
NCATS NIH HHS UL1 TR001111NCATS NIH HHS UL1 TR002489NIDDK NIH HHS F30 DK113728NIDDK NIH HHS P30 DK124723NIDDK NIH HHS R01 DK112939NIDDK NIH HHS UC4 DK108612
6 · The paper itself

Abstract

Individuals with type 1 and advanced type 2 diabetes require daily insulin therapy to maintain blood glucose levels in normoglycemic ranges to prevent associated morbidity and mortality. Optimal insulin delivery should offer both precise dosing in response to real-time blood glucose levels as well as a feasible and low-burden administration route to promote long-term adherence. A series of glucose-responsive insulin delivery mechanisms and devices have been reported to increase patient compliance while mitigating the risk of hypoglycemia. This review discusses currently available insulin delivery devices, overviews recent developments towards the generation of glucose-responsive delivery systems, and provides commentary on the opportunities and barriers ahead regarding the integration and translation of current glucose-responsive insulin delivery designs.

Indexed as

Diabetes Mellitus, Type 2GlucoseBlood GlucoseHumansHypoglycemic AgentsInsulinBlood GlucoseGlucoseHypoglycemic AgentsInsulindiabetes treatmentdrug deliveryglucose-responsiveinsulin administration device

Identifiers

PMID33250274
PMCPMC7758938
OpenAlexW3107262116

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.